Company intelligence / Profile preview

Redwood Dermatology Sciences

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Redwood Dermatology Sciences was a clinical-stage biotechnology company focused on developing innovative topical therapies for dermatological conditions. The company's primary focus was the development of RDS007, a novel topical glucocorticoid receptor modulator designed to treat inflammatory skin diseases like psoriasis and atopic dermatitis while minimizing the systemic side effects typically associated with steroids. The company was founded by industry veterans and was eventually acquired by Maruho Co., Ltd., a leading Japanese pharmaceutical company specializing in dermatology, to bolster their global R&D pipeline.

Therapeutic areas: Dermatology
Modalities: Small molecule
Industry: Biotech

Partnerships

Maruho

Beyond the preview

Go deeper on Redwood Dermatology Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Redwood Dermatology Sciences.

Explore the full profile